Insulin Resistance in Patients with Metabolic Syndrome
MEDS Clinical Medicine · 2022
DOI: 10.23977/medsc.2022.030518 ↗Kurz gefasst
Fachartikel in der Zeitschrift MEDS Clinical Medicine, 2022.
Abstract (Originalsprache)
MS (Metabolic Syndrome), which is a combination of obesity, hypertension, hyperglycemia and abnormal blood lipid levels, has increased the morbidity and mortality of cardiovascular and cerebrovascular diseases, and has become a chronic disease and public health problem seriously endangering human health. The occurrence of MS is closely related to various unhealthy lifestyles. If this is not intervened, the metabolic syndrome is bound to be a global epidemic, causing a huge burden to society. Insulin resistance mainly refers to the decrease of the sensitivity of the body to insulin regulating glucose metabolism, and will affect the metabolism of lipids, proteins, water and electrolytes. Therefore, this study intends to measure the insulin resistance index (HOMA-IR and a series of indicators) of a group of patients with metabolic syndrome and compare them with the normal control group. To investigate the relationship between serum leptin, IL-18, serum amyloid A and insulin resistance in patients with metabolic syndrome, so as to observe the improvement of insulin resistance.
Zitieren
APA
(2022). Insulin Resistance in Patients with Metabolic Syndrome. MEDS Clinical Medicine. https://doi.org/10.23977/medsc.2022.030518
Vancouver
Insulin Resistance in Patients with Metabolic Syndrome. MEDS Clinical Medicine. 2022. doi:10.23977/medsc.2022.030518
BibTeX
@article{euvimed2022,
title = {Insulin Resistance in Patients with Metabolic Syndrome},
journal = {MEDS Clinical Medicine},
year = {2022},
doi = {10.23977/medsc.2022.030518}
}
EUVIMED